Minimal Change Nephrotic Syndrome Associated with Gefitinib and a Successful Switch to Erlotinib
-
- Maruyama Keisuke
- Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
-
- Chinda Junko
- Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
-
- Kuroshima Tatsuki
- Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
-
- Kabara Maki
- Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
-
- Nakagawa Naoki
- Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
-
- Fujino Takayuki
- Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
-
- Yamamoto Yasushi
- Respiratory Center, Asahikawa Medical University Hospital, Japan
-
- Ohsaki Yoshinobu
- Respiratory Center, Asahikawa Medical University Hospital, Japan
-
- Ogawa Yayoi
- GeneticLab Co., Ltd., Japan
-
- Hasebe Naoyuki
- Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan
Search this article
Abstract
Minimal change nephrotic syndrome (MCNS) is a common form of nephrotic syndrome (NS). We herein present the case of a 57-year-old woman with advanced lung adenocarcinoma treated with the tyrosine kinase inhibitor (TKI) gefitinib who developed NS. A renal biopsy revealed minor glomerular abnormalities, and the patient's symptoms improved exclusively with the discontinuation of gefitinib. Therefore, we diagnosed her with MCNS associated with gefitinib treatment. A few months later, however, she developed recurrent lung tumors. Following the challenging initiation of the TKI erlotinib, she achieved remission without proteinuria. We thus conclude that erlotinib is a potential treatment option in patients with NS associated with gefitinib therapy.<br>
Journal
-
- Internal Medicine
-
Internal Medicine 54 (7), 823-826, 2015
The Japanese Society of Internal Medicine
